Table 1 The gene expression signatures of compounds most positively (mean score>0.7 and P<0.01) correlated with that of RRM2 siRNA

From: Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer

CMAP drug Function Mean score No of instances Enrichment P value Specificity Percent non-null
Phenoxybenzamine Non-selective, irreversible alpha antagonist 0.892 4 0.986 0 0.0446 100
Doxorubicin Topoisomerase II inhibitor 0.818 3 0.958 0.0001 0.0447 100
5248896 Unknown 0.812 2 0.974 0.00109 0 100
GW8510 CDK inhibitor 0.754 4 0.915 0.00004 0.0884 100
Trioxysalen A furanocoumarin and a psoralen derivative 0.748 4 0.765 0.00581 0.0261 100
0175029-0000 CDK inhibitor 0.733 6 0.814 0.00008 0.0353 100
Daunorubicin Topoisomerase II inhibitor 0.728 4 0.883 0.0002 0.0404 100
Thioguanosine A purine analog showing antineoplastic activity 0.713 4 0.823 0.00167 0.0412 100
Ellipticine Topoisomerase II inhibitor 0.711 4 0.844 0.00097 0.0608 100
Sulconazole Antifungal medication of the imidazole class 0.708 4 0.738 0.00923 0.0375 100
Morantel Anthelmintic for veterinary use 0.701 5 0.822 0.00038 0 100
  1. Abbreviation: CDK, cyclin-dependent kinase. The results were ranked by their mean scores.